Join the Glecaprevir / pibrentasvir group to help and get support from people like you.
Glecaprevir / pibrentasvir News
Two-Week DAA Prophylaxis Prevents Hep C After Kidney Transplant
TUESDAY, Nov. 28, 2023 – Two-week direct-acting antiviral (DAA) prophylaxis prevents hepatitis C virus (HCV) infection in individuals without HCV viremia who received kidney transplant (KT) from...
FDA Approves Mavyret (glecaprevir/pibrentasvir) Treatment Duration of Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes
NORTH CHICAGO, Ill., Sept. 26, 2019 /PRNewswire/ – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Medwatch Alert: FDA Warns About Rare Occurrence of Serious Liver Injury with Use of Hepatitis C Medicines Mavyret, Zepatier, and Vosevi in Some Patients with Advanced Liver Disease
August 28, 2019 – The Food and Drug Administration (FDA) has received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver...
FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
April 30, 2019 -- The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17. ...
FDA Approves Mavyret (glecaprevir and pibrentasvir) for Hepatitis C
August 3, 2017 – The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis...
Ask a question
To post your own question to this support group, sign in or create an account.